Answers are grounded in this paper and cite their sources.
Twenty‐eight patients with disseminated malignant melanoma were treated with methyl‐1‐(2‐chloroethyl) 3‐(4‐methyl cyclohexyl‐1‐nitrosourea (MeCCNU) administered as a single dose orally every 6 weeks. Six patients (21%) had a complete or partial regression of measurable disease. The median duration of the partial remissions was 2 months and for the 1 complete remission, 18 months. The median survival of those responding to therapy (10.6 months) was significantly longer than those who failed to respond (4.2 months). Regressions of skin, intracutaneous, and nodal disease were most common, but 4 patients had regression of lung metastasis and 1 patient had regression of bone metastasis. Toxicity was primarily delayed thrombocytopenia and to a lesser extent leukopenia occurring within 4 to 6 weeks. Hematopoietic toxicity was significant but manageable. Most patients received treatment as outpatients. The response rate, ease of administration, and absence of sex difference in response make MeCCNU potentially useful in the chemotherapeutic management of disseminated malignant melanoma.
No takes yet. Share an insight, caveat, or question.
Young et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: